Overview of Doxorubicin HEXAL
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Doxorubicin hydrochloride |
| Form | Sterile solution for injection/infusion |
| Pharmacological class | Antineoplastic Agent, Anthracycline |
| General purpose | To stop the growth of abnormal cells |
| Origin | Semi-synthetic (derived from a bacterium) |
What is Doxorubicin HEXAL and What Class Does it Belong To?
Doxorubicin HEXAL is a medicine, distributed by the company HEXAL, classified as an antineoplastic agent, the general term for drugs designed to fight tumors and abnormal cell growth. The medication's active compound is doxorubicin hydrochloride, which belongs to the potent anthracycline family of chemotherapy agents. This specific class is often subcategorized as an antitumor antibiotic, reflecting its historical semi-synthetic origin derived from compounds isolated from the Streptomyces peucetius bacterium. Doxorubicin is a core medicine used for systemic treatment protocols; its efficacy is clinically recognized by major oncological guidelines globally. Doxorubicin is chemically recognized as a hydroxy derivative of daunorubicin, a closely related anthracycline.
Composition, Form, and General Purpose
The medication is a single-ingredient product supplied by HEXAL as a sterile solution for injection/infusion, delivered into the body via the intravenous route (parenteral administration). This specific pharmaceutical form ensures precise and rapid systemic distribution, which is essential for its function against rapidly dividing cells. The drug's general therapeutic purpose is to achieve the slowing or stopping of cancer cell growth by utilizing its cytotoxic action. This function involves the drug acting as a potent Topoisomerase II Inhibitor, a mechanism that ultimately leads to the disruption of the DNA structure and prevents the abnormal cells from copying their genetic material and proliferating uncontrollably. This highly potent mechanism is typically employed in the management of solid tumors and hematological malignancies, as it has the ability to induce cell death in various cancer types.
Regulatory References

